Abstract: A perfusion liquid is suctioned from a perfusion liquid reservoir (16) through the automatic two-way valve (4) by drawing a syringe (5) serving as the perfusion liquid displacement device. For this purpose, the connection from the syringe (5) to the cannula (14) is closed by the two-way valve (4). The two-way valve (4) closes the connection to the perfusion liquid reservoir due to the pressure increase during the insertion of the syringe plunger and opens the connection from the syringe (5) to the cannula (14). A pressure relief valve (7) is attached at the T piece (6), exposing a discharge line (8) in case a threshold pressure is exceeded. A check valve (11) is attached at the extension of the cannula (14), preventing the backflow from the cannula (14) into the remaining system.

Abstract: A method of enrichment of coagulation Factors II, VII, IX and X in preparations obtained from plasma, plasma fractions, or other liquids containing the factors, by adsorbing the factor or factors onto a polymeric matrix that carries an .alpha.-hydroxylamine group, and eluting the factors. When the chromatography conditions are appropriate, it is also easy to prepare a highly concentrated Factor IX preparation with a purity of more than 10 U per mg of protein.

Abstract: A method of preparing a solution of lactic or colostric immunoglobulins or both by processing milk or colostrum or both accompanied by precipitation of the caseins, characterized in that milk or colostrum or both are acidified to a pH of 4.0-5.5, subjected to cross-flow filtration in a filtration unit with a mean pore size of 0.1-1.2 .mu.m, and the low-molecular components removed by means of further cross-flow filtration in another filtration unit with a limit of separation of 5 000-80 000 daltons, as well as an agent for treating bacterial and viral infections that consists of a solution obtained by means of said method.

Abstract: To provide a method that allows the preparation, not only from human blood but also from animal blood and in quantities large enough for clinical applications, of highly purified hemoglobin solutions that can be employed for the treatment of humans and that are free of plasma proteins and residual stroma lipids (a) a starting material that contains erythrocytes is pumped over a filter unit that has a pore size between 0.1 and 1.2 .mu.m in circulation against an isotonic washing solution, (b) the product of (a) is hemolyzed and pumped over an ultrafiltration unit that has a permeability of 80,000 to 100,000 D in circulation against water, and (c) the ultrafiltrate obtained in stage (b) is pumped and diafiltered over an ultrafiltration unit that has a permeability of 10,000 to 50,000 D in circulation against water, whereby concentration is conducted before and/or after diafiltration.

Abstract: A process for obtaining hepatitis-safe, sterile, pyrogen- and stroma-free hemoglobin solutions of low potassium content comprising stirring an erythrocyte concentrate with about 1 to 6-times its volume of an about 5 to 15% aqueous solution of a sugar, sugar alcohol or high-molecular-weight colloid, adjusting the pH of the resulting suspension to about 5 to 6.5 with an acid which is physiologically tolerable as salt, allowing the erythrocytes to settle, removing the supernatant from the sediments, adjusting the pH of the sediment to about 7 to 8, homogenizing the sediment, adjusting its hematocrit to about 55 to 60%, treating the mass with a dilute beta-propiolactone solution, hemolyzing the residual solids and forming a suspension thereof, contacting the suspension with a cation exchanger in H.sup.+ form until the pH has decreased to about 5 to 5.5 thereby to precipitate the stroma, separating from the liquid the cation exchanger and precipitated stroma, and adjusting the pH to about 7.2 to 7.6.